GMA
The study shows that urolithin A activates the AHR–NLRP6–IL‑18 axis in intestinal epithelial cells, with observations also made in tissue from people with IBD.
Urolithin A is a metabolite produced by some gut microbes from ellagitannins found in foods including pomegranate, walnuts and berries. The study examines its direct action on intestinal epithelial cells.
Authors describe activation of the AHR–NLRP6–IL‑18 axis, associated with epithelial regeneration, mucus production and stronger barrier integrity in experimental models. The analysis also includes human tissue from people with inflammatory bowel disease.
The value lies in the mechanism, not a clinical claim. Tissue, cell and animal findings do not establish supplementation efficacy in humans; trials with a defined dose, formulation, population and endpoint are still required.
It strengthens the polyphenols → microbiota → metabolite → gut barrier pathway and the case for ingredients differentiated by a measurable mechanism.
Predominantly mechanistic and preclinical evidence. It does not show that urolithin A supplementation prevents or treats IBD or other intestinal disorders in humans.
Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.
Read the original source · Nature Communications / PubMed